Quite a number died receiving Covid during the CD12 trial and EIND. No drug will save everyone.
However, the Brazilian trials are marked improved over CD12.
1. Four doses rather than two.
2. Critical receive IV rather than SQ. Poor pharmacokinetics (slow absorption) in patients with shock, as vasoconstriction prevents adequate perfusion of peripheral tissues.
3. Administration to patients admitted within 72 hours for moderate trial and intubated within 72 for critical trial.
The trial improvements are based upon what has been learned in CD12 as release of the FDA shackles on CD12.
A shout-out to occasional poster Rockleo (physician and Cytodyn investor), who has noted that patients who have been hospitalized and/or ventilated develop pulmonary fibrosis and other permanent structural changes that are not easily reversed.
These improvements to the trials' design will finally allow Leronlimab to show its true efficacy.